This study aimed to analyze the correlation between ganglion cell complex thickness (GCCT) and vision compared with the choroidal thickness (CT) and central retinal thickness (CRT) in relation to the outcomes of intravitreal aflibercept treatment for choroidal neovascular membranes secondary to age-related macular degeneration (AMD).
Methods
This was a prospective, observational study. Forty-three eyes of 38 patients with wet AMD received a monthly loading dose of 2 mg aflibercept by intravitreal injection (IVI) during the first 3 months and were then followed at regular monthly intervals for an average of 10 months by a pro re nata regimen. All patients were examined using spectral domain-optic coherence tomography (OCT) and enhanced depth imaging OCT. According to their response to IVI treatment in the third month, patients were divided into 2 groups, both functionally and anatomically.
Results
Three-month GCCT and optic disc retinal nerve fiber layer thickness (ODRNFLT) had the most correlation with the 10-month vision (p = 0.002, p = 0.02, respectively). While baseline GCCT was most correlated with the functional response, baseline CRT was most correlated with the anatomical response (p = 0.01, p = 0.004, respectively).
Conclusions
The results suggest that a reduction in 3-month GCCT indicates a good long-term vision outcome, while a reduction in 3-month ODRNFLT shows a poor long-term vision outcome. The literature suggests that this study is the first to demonstrate that baseline GCCT is more strongly correlated with the functional response than it is with CT and CRT. Hence, GCCT has a prognostic value for vision impairment.
BresslerNM. Early detection and treatment of neovascular age-related macular degeneration. The Journal of the American Board of Family Practice2002; 15: 142–152.
SayenAHubertIBerrodJ-P. Age related macular degeneration. La Revue du praticien,2011; 61: 159–164.
5.
CheungLKEatonA. Age-related macular degeneration. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy2013; 33: 838–855.
6.
ShinJYKwonKYByeonSH. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration. Acta Ophthalmol (Copenh)2015; 93: 524–532.
7.
BandelloFParodiMBAugustinA. Anti-VEGF. Basel, Switzerland: Karger Medical and Scientific Publishers, 2010.
KanskiJJBowlingB. Clinical ophthalmology: a systematic approach. Edinburgh, Scotland: Elsevier Health Sciences, 2011.
10.
GheorgheAMahdiLMusatO. Age-related macular degeneration. Romanian Journal of Ophthalmology2015; 59: 74–77.
11.
AbdolrahimzadehSGharbiyaMFormisanoM, et al.Anti-vascular endothelial growth factor intravitreal therapy and macular ganglion cell layer thickness in patients with neovascular age-related macular degeneration. Curr Eye Res2019; 44(9): 1000–1005.
12.
BeckMMunkMREbneterA, et al.Retinal ganglion cell layer change in patients treated with anti–vascular endothelial growth factor for neovascular age-related macular degeneration. Am J Ophthalmol2016; 167: 10–17.
13.
CakırASagdicSDuzgunE, et al.Long-term effects of intravitreal ranibizumab treatment on retinal ganglion cell complex and choroidal thickness. New Front Ophthalmol2018; 4: 1–5.
14.
CamachoPDutra-MedeirosMPárisL. Ganglion cell complex in early and intermediate age-related macular degeneration: evidence by SD-OCT manual segmentation. Ophthalmologica Journal international d'ophtalmologie International journal of ophthalmology Zeitschrift fur Augenheilkunde2017; 238: 31–43.
15.
CelikECakırBTurkogluEB, et al.Effect of cataract surgery on subfoveal choroidal and ganglion cell complex thicknesses measured by enhanced depth imaging optical coherence tomography. Clinical Ophthalmology (Auckland, NZ)2016; 10: 2171.
16.
IriyamaAChenYNTamakiY, et al.Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol2007; 91: 1230–1233.
17.
IulianoLFogliatoGGorgoniF, et al.Idiopathic epiretinal membrane surgery: safety, efficacy and patient related outcomes. Clinical Ophthalmology (Auckland, NZ)2019; 13: 1253.
18.
MedeirosNECurcioCA. Preservation of ganglion cell layer neurons in age-related macular degeneration. Invest Ophthalmol Visual Sci2001; 42: 795–803.
19.
ParkH-YLKimJHParkCK. Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model. Am J Pathol2014; 184: 1752–1762.
20.
PerdicchiAPelusoGIacovelloD, et al.Ganglion cell Complex evaluation in exudative age-related macular degeneration after repeated intravitreal injections of ranibizumab. BioMed Res Int2015; 2015: 6.
21.
ShaheerMAmjadASaleemZ. Retinal ganglion cell Complex changes after intravitreal bevacizumab for diabetic macular edema. Journal of the College of Physicians and Surgeons–Pakistan: JCPSP2019; 29: 426–429.
22.
ZucchiattiICicinelliMVParodiMB, et al.Effect of intravitreal ranibizumab on ganglion cell Complex and peripapillary retinal nerve fiber layer in neovascular age-related macular degeneration using spectral domain optical coherence tomography. Retina2017; 37: 1314–1319.
23.
baldiviesoVCSinaiMJQuiroz-MercadoH, et al.The effect of anti VEGF therapy for AMD on the retinal ganglion cell Complex (GCC) measured with Fourier-domain optic coherence tomography (FD- OCT). Invest Ophthalmol Visual Sci2012; 53: 2922–2922.
24.
LeeJYKimHC. Ganglion cell layer thickness after anti-vascular endothelial growth factor treatment in retinal vein occlusion. J Korean Ophthalmol Soc2016; 57: 63–70.
25.
ZhangXDastiridouAFrancisBA, et al.Baseline Fourier-domain optical coherence tomography structural risk factors for visual field progression in the advanced imaging for glaucoma study. Am J Ophthalmol2016; 172: 94–103.
26.
El-AshryMFLascaratosGDhillonB. Evaluation of the effect of intravitreal ranibizumab injections in patients with neovascular age related macular degeneration on retinal nerve fiber layer thickness using optical coherence tomography. Clin Ophthalmol2015; 9: 1269–1274.
27.
FungAELalwaniGARosenfeldPJ, et al.An optical coherence tomography-guided, Variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol2007; 143: 566–583. e562.
28.
HoACBusbeeBGRegilloCD, et al.Twenty-four-Month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology2014; 121: 2181–2192.
29.
KangHMKwonHJYiJH, et al.Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. Am J Ophthalmol2014; 157: 1013–1021. e1011.
30.
KimDYJoeSGYangSJ, et al.The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy. Korean J Ophthalmol2015; 29: 160–167.
31.
KoizumiHKanoMYamamotoA, et al.Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration. Ophthalmology2016; 123: 617–624.
32.
KoizumiHYamagishiTYamazakiT, et al.Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefe's Arch Clin Exp Ophthalmol2011; 249: 1123–1128.
33.
LalwaniGARosenfeldPJFungAE, et al.A Variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol2009; 148: 43–58. e41.
34.
ManjunathVGorenJFujimotoJG, et al.Analysis of choroidal thickness in age-related macular degeneration using spectral-domain optical coherence tomography. Am J Ophthalmol2011; 152: 663–668.
35.
Martinez-de-la-CasaJMRuiz-CalvoASaenz-FrancesF, et al.Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal RanibizumabIntravitreal ranibizumab effects on RNFL thickness. Invest Ophthalmol Visual Sci2012; 53: 6214–6218.
36.
MrejenSJungJJChenC, et al.Long-Term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration. J Clin Med2015; 4: 1380–1402.
37.
RayessNRahimyEYingG-s, et al.Baseline choroidal thickness as a predictor for response to anti–vascular endothelial growth factor therapy in diabetic macular edema. Am J Ophthalmol2015; 159: 85–91. e83.
38.
RegilloCDBrownDMAbrahamP, et al.Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol2008; 145: 239–248. e235.
39.
YiuGChiuSJPetrouPA, et al.Relationship of central choroidal thickness with age-related macular degeneration status. Am J Ophthalmol2015; 159: 617–626. e612.
40.
YiuGManjunathVChiuSJ, et al.Effect of anti–vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema. Am J Ophthalmol2014; 158: 745–751. e742.
41.
ArevaloJFSanchezJGWuL, et al.Primary intravitreal bevacizumab for diffuse diabetic macular edema: the pan-American collaborative retina study group at 24 months. Ophthalmology2009; 116: 1488–1497. e1481.
42.
ChoWBOhSBMoonJW, et al.Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. RETINA2009; 29: 516–522.
43.
FlaxelCSchainMBHamonSC, et al.Prospective randomized controlled trial of combination ranibizumab (lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study. RETINA2012; 32: 417–423.
44.
ShoeibiNAhmadiehHEntezariM, et al.Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long-term results of a clinical trial. J Ophthalmic Vis Res2013; 8: 99–106.
45.
ArevaloJFLasaveAFWuL, et al.Intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: 5-year results of the pan-American collaborative retina study group. RETINA2016; 36: 859–867.
46.
DemircanAAlkinZYesilkayaC, et al.Comparison of intravitreal aflibercept and ranibizumab following initial treatment with ranibizumab in persistent diabetic macular edema. J Ophthalmol2018; 2018: 4171628.
47.
LeeJYLeeDHLeeJY, et al.Correlation between subfoveal choroidal thickness and the severity or progression of nonexudative age-related macular DegenerationSFChT and nonexudative AMD. Invest Ophthalmol Visual Sci2013; 54: 7812–7818.
48.
HorsleyMBMandavaNMaycotteMA, et al.Retinal nerve fiber layer thickness in patients receiving chronic anti–vascular endothelial growth factor therapy. Am J Ophthalmol2010; 150: 558–561. e551.
49.
SobacıGGüngörRÖzgeG. Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. Int J Ophthalmol2013; 6: 211.
BouteleuxVKodjikianLMendesM, et al.Increased choroidal thickness: a new feature to monitor age-related macular degeneration recurrence. Graefe's Arch Clin Exp Ophthalmol2019; 257: 699–707.
52.
InvernizziABenattiECozziM, et al.Choroidal structural changes correlate with neovascular activity in neovascular age related macular degeneration. Invest Ophthalmol Visual Sci2018; 59: 3836–3841.
53.
SaidhaSSotirchosESIbrahimMA, et al.Relationships of the inner nuclear layer of the retina with clinicoradiologic disease characteristics in multiple sclerosis; aretrospective study. Lancet Neurol2012; 11: 963–972.
54.
MukkamalaLBhagatNZarbinM. Practical lessons from protocol T for the management of diabetic macular edema. Dev Ophthalmol2017; 60: 109–124.
55.
TufailAMargaronPGuerinT, et al.Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA. Br J Ophthalmol2020; 104: 672–677.
56.
KocicIHiranoYHiraokaM. Ionic basis for membrane potential changes induced by hypoosmotic stress in Guinea-pig ventricular myocytes. Cardiovasc Res2001; 51: 59–70.
57.
GoncziMSzentandrassyNFulopL, et al.Hypotonic stress influence the membrane potential and alter the proliferation of keratinocytes in vitro. Exp Dermatol2007; 16: 302–310.
58.
KajimotoKShaoDTakagiH, et al.Hypotonic swelling-induced activation of PKN1 mediates cell survival in cardiac myocytes. American Journal of Physiology – Heart and Circulatory Physiology2011; 300: H191–H200.
59.
YanYDingYMingB, et al.Increase in hypotonic stress-induced endocytic activity in macrophages via ClC-3. Mol Cells2014; 37: 418–425.
60.
DibasAYangM-HBobichJ, et al.Stress-induced changes in neuronal aquaporin-9 (AQP9) in a retinal ganglion cell-line. Pharmacol Res2007; 55: 378–384.
61.
ChvátalAAnděrováMKirchhoffF. Three-dimensional confocal morphometry – a new approach for studying dynamic changes in cell morphology in brain slices. J Anat2007; 210: 671–683.
